โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

[18F]PI-2620 Phase 3 Histopathological Study

Sponsored by Life Molecular Imaging Ltd

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Jan 7, 2026

Phase

Clinical Trial

Sponsor

Life Molecular Imaging Ltd

Enrollment Target

200

Start Date

Dec 2022

๐Ÿ“Š
1 of 200 participants interested
1% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Who Can Participate

Inclusion Criteria

Only subjects who meet all of the following criteria will be eligible for enrollment into the study: 1. Males and females aged 50 years and over 2. Have a projected life expectancy of โ‰ค 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer) 3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies) 4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria

Subjects will be excluded from the enrollment if they:

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

200 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

Life Molecular Imaging Ltd

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Phoenix

Arizona

Location available
View Phoenix location page
RECRUITING

Sun City

Arizona

Location available
View Sun City location page
RECRUITING

Los Angeles

California

Location available
View Los Angeles location page
RECRUITING

Murrieta

California

Location available
View Murrieta location page
RECRUITING

San Francisco

California

Location available
View San Francisco location page
RECRUITING

Hialeah

Florida

Location available
View Hialeah location page
RECRUITING

Jacksonville

Florida

Location available
View Jacksonville location page
RECRUITING

Lady Lake

Florida

Location available
View Lady Lake location page
RECRUITING

Maitland

Florida

Location available
View Maitland location page

๐Ÿ“ And 16 more locations available

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Leukemia Trials by City

Browse all leukemia clinical trials in these cities โ€” not just this study.

Looking for Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease Treatment in Phoenix?

Join others in Arizona exploring innovative treatment options through clinical research

Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease Treatment Options in Phoenix, Arizona

If you're searching for Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease treatment in Phoenix, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Phoenix, Sun City, Los Angeles and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Arizona
Now Enrolling
Up to 200 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Based on the limited information provided, this appears to be a diagnostic imaging study using a radiotracer. [18F]PI-2620 is typically used for tau protein imaging in neurodegenerative diseases. Alzheimer's Disease Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05641688. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.